Relation between Vitamin B12 Levels and Smell Affection in COVID-19 Patients

Osama A. Elsayad1 Said Mohammed Abdou1

1 Benha University Faculty of Medicine, Tanta University Faculty of Medicine, Tanta, Egypt

Address for correspondence Osama A. Elsayad, Benha University Faculty of Medicine, Tanta University Faculty of Medicine, El Bahr St. Tanta Qism 2, Tanta, Gharbia Governorate 31111, Egypt (e-mail: drsayado@yahoo.com).

Abstract

Introduction Olfactory and gustative alterations are frequent in the initial stages of the COVID-19 infection. Vitamin B12 deficiency has been linked to olfactory dysfunction.

Objective The present study aimed to assess the relationship between vitamin B12 levels and smell affection in COVID-19 patients.

Methods The present study included 201 laboratory-confirmed COVID-19 patients. Smell affection was assessed using self-rated olfactory function. Serum vitamin B12 levels were assessed using commercial enzyme-linked immunosorbent assay (ELISA) kits.

Results According to the smell function assessment, the patients were classified into three categories: normal osmesis (n = 77), hyposmia (n = 49), and anosmia (n = 75) (► Fig. 1). Four weeks later, 195 patients (97.0%) had their normal smell function restored. The remainder 6 patients included 4 anosmic and 2 hyposmic patients. Patients with hyposmia or anosmia had significantly lower vitamin B12 levels when compared with patients with normal osmesis (median [IQR]: 363.0 [198.0–539.0] versus 337.0 [175.0–467.0] and 491.0 [364.5–584.5] pg/ml, respectively, p < 0.001).

Conclusion Vitamin B12 appears to have some contribution to smell affection in patients with COVID-19 infection.

Introduction

In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), initially known as the 2019 novel coronavirus (2019-nCoV), started in China in Wuhan. Since then, this novel virus, also named as coronavirus disease 2019 (COVID-19), has crossed all countries’ borders with dramatic spread all over the world until the World Health Organization (WHO) defined it as a pandemic disease on March 11, 2020.1

The novel COVID-19 is presented mainly by lower respiratory tract-related manifestations such as fever, cough, dyspnea, and chest tightness that could progress quickly to acute respiratory distress syndrome (ARDS).2 However, COVID-19 also leads to different upper respiratory tract-related manifestations comprising sore throat, smell dysfunction, and nasal congestion.3 The olfactory and gustative alterations are frequent in the initial stages of the infection.2–5

Of note, a wide variation has been reported between Chinese and European studies regarding the prevalence of taste and smell affection. In one Chinese study, anosmia and ageusia were reported in 5.1% and 5.6% of patients,
respectively. In contrast, the frequency of taste and smell disorders in European studies ranged between 19.4% and 88%. Vitamin B-12 deficiency is expected to result in low serum or plasma concentrations of total vitamin B-12 and holotranscobalamin, accompanied by high methylmalonic acid (MMA) and total plasma homocysteine (tHcy). Severe vitamin B-12 deficiency is characterized clinically by megaloblastic anemia and neurodegenerative changes of the central and peripheral systems. Neurological effects may include cognitive impairment, peripheral neuropathy, subacute combined degeneration of the spinal cord, and psychiatric disorders.

The present study aimed to assess the relation between vitamin B12 levels and smell affection in COVID-19 patients.

**Methods**

The present prospective study was conducted at a private hospital at the “BLINDED FOR REVIEW PROCESS” between May 2020 and June 2021. The study protocol was approved by the local ethics committee of “BLINDED FOR REVIEW PROCESS”, and all patients signed an informed consent form before participation. The study included 201 COVID-19 patients with positive reverse-transcriptase polymerase chain reaction (RT-PCR) test of a nasopharyngeal swab. Patients were excluded from the study if they had history of smell dysfunction or nasopharyngeal or neurological disorders that may affect smell function and were subjected to careful history taking, thorough clinical examination and standard laboratory assessment.

The COVID-19 severity was assessed using the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) criteria. Patients were classified to have severe disease if they had ≥ 1 major criterion (1. septic shock with need for vasopressors or 2. invasive mechanical ventilation) or ≥ 3 minor criteria (1. respiratory rate ≥ 30 breaths/min., 2. PaO2/FiO2 ratio ≤ 250, 3. multilobar infiltrates, 4. confusion/disorientation, 5. uremia (BUN level ≥ 20 mg/dL), 6. leukopenia as a result of infection alone (WBC count < 4,000 cells/mL), 7. thrombocytopenia (platelets count < 100,000/mL), 8. hypothermia (core temperature < 36°C), 9. hypotension requiring aggressive fluid resuscitation).

Smell affection was quantitively assessed using the clinical test described by Cain et al. The test combines threshold testing and odor identification. According to the composite score, patients were classified into five categories of functioning: normal osmos, mild hyposmia, moderate hyposmia, severe hyposmia, and anosmia. For convenience, we classified our patients into three categories: normal osmosis, hyposmia (whatever its severity), and anosmia. Evaluation of smell function was performed at baseline and after 4 weeks of diagnosis. Serum vitamin B12 levels were assessed using commercial enzyme-linked immunosorbent assay (ELISA) kits.

Data obtained from the present study were presented as mean and standard deviation (SD) or number and percentage. Continuous variables were compared using the one-way analysis of variance (ANOVA) with posthoc LSD comparisons. The categorical data were compared using the Pearson correlation analysis. A receiver operator characteristic (ROC) curve analysis was used to identify diagnostic performance of investigated marker. All statistical tests were performed using IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., Armonk, NY, USA). A p-value lower than 0.05 was considered statistically significant.

**Results**

The present study included 201 COVID-19 patients. According to smell function assessment, the patients were classified into three categories: normal osmosis (n = 77), hyposmia (n = 49), and anosmia (n = 75) (Fig. 1). Four weeks later, 195 patients (97.0%) restored normal smell function. The remainder six patients included four anosmic and two hyposmic patients.

The comparison between patients with and without smell affection regarding the clinical and laboratory data revealed that patients with smell affection are significantly younger than patients with normal sense of smell (Table 1). It was also shown that patients with hyposmia or anosmia had significantly lower vitamin B12 levels when compared with patients with normal osmosis (median interquartile range [IQR]: 363.0 [198.0–539.0] versus 337.0 [175.0–467.0] and 491.0 [364.5–584.5] pg/mL respectively, p < 0.001). Also, anosmic patients were found to have significantly lower vitamin B12 levels in comparison to hyposmic counterparts (Table 1, Fig. 2).

The correlation analysis identified no significant correlation between vitamin B12 levels and other laboratory or clinical parameters (Table 2). The ROC curve analysis showed good performance of vitamin B12 levels in identification of smell affection in COVID-19 patients (area under curve [AUC] 95% confidence interval [95% CI]: 0.69 [0.61–0.76]) with a sensitivity and specificity of 67.7% and 63.6%, respectively (Fig. 3).

**Discussion**

In the present study on 201 COVID-19 patients, 124 patients (61.7%) had some degree of smell affection. They comprised 49 patients (24.4%) with hyposmia and 75 patients (37.3%) with anosmia. In comparison, one study from Saudi Arabia...
Table 1 Clinical and laboratory findings in the studies patients (n = 201)

|                | All patients N = 201 | Normal osmesis N = 77 | Hyposmia N = 49 | Anosmia N = 75 | P-value |
|----------------|----------------------|-----------------------|-----------------|----------------|---------|
| Age (years) median (IQR) | 31.0 (27.0–36.0) | 33.0 (28.0–39.0) | 32.0 (28.5–38.0) | 30.0 (26.0–33.0) | 0.003   |
| Male/female n       | 132/69              | 47/30                 | 35/14           | 50/25          | 0.48    |
| Covid-19 severity n (%) |                    |                      |                 |                |         |
| Mild               | 30 (14.9)           | 65 (84.4)            | 38 (77.6)       | 68 (90.7)      | 0.13    |
| Severe             | 171 (85.1)          | 12 (15.6)            | 11 (22.4)       | 7 (9.3)        |         |
| Laboratory findings median (IQR) |                  |                      |                 |                |         |
| Hb (gm/dL)         | 13.0 (12.0–14.0)    | 12.8 (11.8–14.0)     | 13.0 (11.5–14.2) | 13.2 (12.0–14.0) | 0.27    |
| WBCs (× 10^3/mL)   | 6.5 (4.5–10.0)      | 6.5 (4.0–10.0)       | 6.0 (4.6–10.7)  | 7.0 (4.5–10.0) | 0.44    |
| Platelets (× 10^3/ml) | 212.0 (162.5–260.0) | 200.0 (139.5–250.0)  | 200.0 (160.0–239.5) | 215.0 (180.0–259.0) | 0.17    |
| CRP (mg/dL)        | 88.0 (44.5–126.5)   | 91.0 (41.0–145.5)    | 93.0 (50.5–122.5) | 75.0 (41.0–118.0) | 0.42    |
| Procalcitonin (µg/L) | 0.1 (0.08–0.2)     | 0.1 (0.1–0.2)        | 0.15 (0.08–0.2) | 0.1 (0.08–0.2) | 0.96    |
| LDH (U/L)          | 614.0 (414.0–908.0) | 527.0 (385.5–922.5)  | 621.0 (454.5–911.5) | 618.0 (431.0–831.0) | 0.38    |
| Ferritin (µg/L)    | 663.0 (442.0–1,456.5) | 648.0 (408.5–1,549.0) | 800.0 (416.0–1,598.5) | 713.0 (507.0–1,324.0) | 0.55    |
| PT (sec.)          | 13.9 (13.0–15.8)    | 14.3 (13.2–15.8)     | 14.8 (13.3–16.7) | 14.5 (13.0–16.0) | 0.36    |
| APTT (sec.)        | 34.0 (30.0–42.0)    | 35.0 (31.0–40.5)     | 36.0 (32.0–45.5) | 33.0 (30.0–44.0) | 0.27    |
| D-dimer (ng/mL)    | 1162.0 (746.5–2,122.0) | 978.0 (732.0–2,122.0) | 1290.0 (810.0–2,549.0) | 980.0 (750.0–1,750.0) | 0.35    |
| Fibrinogen (gm/dL) | 3.7 (3.0–4.8)       | 3.7 (3.1–4.7)        | 4.1 (3.0–5.2)   | 3.5 (3.0–4.5)  | 0.23    |
| Creatinine (mg/dL) | 1.1 (0.8–1.3)       | 1.0 (0.9–1.3)        | 0.9 (0.9–1.25)  | 0.9 (0.8–1.3)  | 0.1     |
| Urea (mg/dL)       | 50.0 (38.0–76.0)    | 51.0 (38.0–76.5)     | 56.0 (41.0–80.0) | 45.0 (37.0–72.0) | 0.42    |
| Albumin (gm/dL)    | 3.2 (3.0–4.0)       | 3.5 (3.0–3.9)        | 3.5 (3.1–3.8)   | 3.5 (3.1–4.0)  | 0.88    |
| AST (U/L)          | 45.0 (29.0–72.5)    | 47.0 (34.5–76.0)     | 41.0 (28.0–76.0) | 42.0 (27.0–67.0) | 0.19    |
| ALT (U/L)          | 51.0 (34.0–80.0)    | 59.0 (37.0–81.0)     | 48.0 (33.0–80.0) | 44.0 (26.0–76.0) | 0.08    |
| O2 saturation (%)  | 90.0 (80.0–95.0)    | 92.0 (80.0–95.0)     | 90.0 (80.0–94.0) | 92.0 (85.0–95.0) | 0.07    |
| Vitamin B12 (pg/mL) | 403.0 (212.0–544.5) | 491.0 (364.5–584.5)  | 363.0 (198.0–539.0) | 337.0 (175.0–467.0) | < 0.001 |

Abbreviations: aPTT, activated partial thromboplastin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; Hb, hemoglobin; IQR, interquartile range; LDH, lactate dehydrogenase; PT, prothrombin time; WBCs, white blood cells.

Fig. 2 Vitamin B12 levels in the studied patients.
noted that olfactory dysfunction was reported by 53% of COVID-19 patients, of which 32.7% were anosmic and 20.3% were hyposmic. In another study, anosmia was diagnosed in 44.0% of 500 COVID-19 patients from the United Arab Emirates, while anosmia was reported in 67.0% of 288 Brazilian COVID-19 patients. One large meta-analysis including data from 107 studies and 32,142 COVID-19 patients found that anosmia was reported in 12,038 patients with a prevalence of 38.2% (95% CI: 36.5%, 47.2%). This variation may be explained by the different tools used for diagnosis of olfactory dysfunction in different studies. In addition, other clinical or genetic factors may be involved.

Four weeks later, 195 patients (97.0%) had their normal smell function restored. The remainder six patients included four anosmic and two hyposmic patients. In the study of Babaie et al., 88.5% of patients had their sense of smell restored by 4 weeks, while in the study of Kumar et al., 97.0% of patients recovered it within 2 weeks.

Interestingly, the present study found that patients with smell affection were significantly younger than patients with normal smell, which is in line with the former study of Mubarak et al.

In this study, we assessed the relation between vitamin B12 levels and smell affection scores in COVID-19 patients. In the first and 4 weeks, groups with higher vitamin B12 levels had significantly better self-rated smell affection scores.

The association between vitamin B12 deficiency and smell affection was previously reported. The study of Derin et al. showed a relation between vitamin B12 deficiency and olfactory dysfunction. Interestingly, one recent report recognized good response of COVID-19 patients with olfactory affection to vitamin B12 supplementation.

The mechanisms explaining the role of vitamin B12 in olfactory dysfunction remain to be elucidated. However, the main suggested mechanism is olfactory neuronal toxicity caused by elevated homocysteine levels due to inefficient methylation of homocysteine into methionine in patients with vitamin B12 deficiency.

Conclusion

In conclusion, vitamin B12 appears to have some contribution to smell affection in patients with COVID-19 infection. The findings of the present study may have significant clinical implications, particularly in patients with long-term post-COVID-19 infection. The assessment of vitamin B12 levels in those patients may provide a clue for appropriate treatment. However, the value of vitamin B12 supplementation as a therapeutic strategy requires well-designed randomized clinical studies to be confirmed.

Conflict of Interests

The authors have no conflict of interests to declare.

References

1. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579 (7798):266–269
2. Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-
moderate forms of the coronavirus disease (COVID-19): a multi-
center European study. Eur Arch Otorhinolaryngol 2020;277(08):
2251–2261. Doi: 10.1007/s00405-020-05965-1
3 Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia: A review
based on up-to-date knowledge. Am J Otolaryngol 2020;41(05):
102581
4 Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and Ageusia:
Common Findings in COVID-19 Patients. Laryngoscope 2020;130
(07):1787. Doi: 10.1002/lary.28692
5 Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in
COVID-19 infection. A novel syndrome? Rhinology 2020;58(03):
299–301. Doi: 10.4193/Rhin20.114
6 Mao L, Wang M, Chen S, et al. Neurological manifestations of hospital-
ized patients with COVID-19 in Wuhan, China: a retrospective case
series study. MedRXiv 2020. Doi: 10.1101/2020.02.22.200.26500
7 Green R, Miller JW. Vitamin B12. In: Zempleni J, Suttie JW,
Gregory JF III, Stover PJ, eds. Handbook of vitamins. 5th ed.
Boca Raton (FL):: CRC Press; 2014:447–489
8 Selhub J, Miller JW. The pathogenesis of homocysteinemia:
interruption of the coordinate regulation by S-adenosylmethio-
nine of the remethylation and transsulfuration of homocysteine.
Am J Clin Nutr 1992;55(01):131–138
9 Hemmer B, Glocker FX, Schumacher M, Deuschl G, Lücking CH.
Subacute combined degeneration: clinical, electrophysiological,
and magnetic resonance imaging findings. J Neurol Neurosurg
Psychiatry 1998;65(06):822–827
10 Rosenberg IH. Effects of folate and vitamin B12 on cognitive
function in adults and the elderly. Food Nutr Bull 2008;29(2,
Suppl):S132–S142
11 Metlay JP, Waterer GW. Update in adult community-acquired
pneumonia: key points from the new American Thoracic Society/Infectious Diseases Society of America 2019 guideline.
Curr Opin Pulm Med 2020;26(03):203–207
12 Cain WS, Gent J, Catalanotto FA, Goodspeed RB. Clinical evaluation
of olfaction. Am J Otolaryngol 1983;4(04):252–256
13 Mubaraki AA, Alraiai GT, Sibyani AK, Alhulayfi RM, Alzaidi RS,
Almalki HS. Prevalence of anosmia among COVID-19 patients in
Taif City, Kingdom of Saudi Arabia. Saudi Med J 2021;42(01):
38–43
14 Al-Rawi NH, Sammouda AR, AlRahin EA, et al. Prevalence of
Anosmia or Ageusia in Patients With COVID-19 Among
United Arab Emirates Population. Int Dent J 2022;72(02):
249–256
15 Sampaio Rocha-Filho PA, Albuquerque PM, Carvalho LCLS, Dan-
dara Pereira Gama M, Magalhães JE. Headache, anosmia, ageusia
and other neurological symptoms in COVID-19: a cross-sectional
study. J Headache Pain 2022;23(01):2
16 Mutiawati E, Fahriani M, Mamada SS, et al. Anosmia and dysgeusia
in SARS-CoV-2 infection: incidence and effects on COVID-19
severity and mortality, and the possible pathobiology mecha-
nisms - a systematic review and meta-analysis. F1000 Res 2021;
10:40
17 Babaie A, Iravani K, Malekpour B, Golkhar B, Soltaniesmaeili A,
Hosseinialhashemi M. Factors associated with anosmia recovery
rate in COVID-19 patients. Laryngoscope Investig Otolaryngol
2021;6(06):1248–1255
18 Kumar V, Singla S, Gupta N, et al. The incidence of anosmia in
patients with laboratory-confirmed COVID 19 infection in India:
An observational study. J Anaesthesiol Clin Pharmacol 2021;37
(01):51–56
19 Derin S, Koseoglu S, Sahin C, Saham M. Effect of vitamin B12
deficiency on olfactory function. Int Forum Allergy Rhinol 2016;6
(10):1051–1055. Doi: 10.1002/alr.21790
20 Pissurno NSCA, Lichs GGC, Santos EJLD, Druzian AF, Oliveira
SMDVL, Paniago AMM. Anosmia in the course of COVID-19: A
case report. Medicine (Baltimore) 2020;99(31):e21280. Doi:
10.1097/MD.00000000000021280
21 Torsvik I, Ueland PM, Markestad T, Bjerke-Monsen AL. Cobalamin
supplementation improves motor development and regurgita-
tions in infants: results from a randomized intervention study.
Am J Clin Nutr 2013;98(01):1233–1240
22 Gupta PK, Garg RK, Gupta RK, et al. Diffusion tensor tractography
and neuropsychological assessment in patients with vitamin B12
deficiency. Neuroradiology 2014;56(02):97–106